Relapsed/Refractory CLL Treatment Options with Dr. Kerry Rogers
![Relapsed/Refractory CLL Treatment Options with Dr. Kerry Rogers image](https://healthtree.org/images-resize?width=1000&height=1000&imageUrl=https%253A%252F%252Ffirebasestorage.googleapis.com%252Fv0%252Fb%252Fhealthtree-production.appspot.com%252Fo%252Fgallery%25252Fpublic%25252FScreen%252520Shot%2525202024-03-19%252520at%2525202.39.55%252520PM_eb37d920-0bf2-4b86-9f81-37bcdbb42910.png%253Falt%253Dmedia)
Event Description
What treatment options do CLL patients have after venetoclax and covalent BTK inhibitors? Is the next treatment already FDA-approved, or is it administered in clinical trials? What is the best way for patients to navigate this decision-making process? Join the group discussion with Dr. Kerry Rogers, CLL specialist from the Ohio State University Comprehensive Cancer Center, to discuss this important topic!
Schedule & Agenda
![The panelist Megan Heaps](https://firebasestorage.googleapis.com/v0/b/healthtree-production.appspot.com/o/gallery%2Fpublic%2F1682188565594_217313db-c2d5-4ac9-8426-78e017798142_dca2a66a-69e0-470f-9d72-a578050fee9e.jpg?alt=media)
Megan introduces the agenda of the event and featured speaker Dr. Kerry Rogers.
![The panelist Megan Heaps](https://firebasestorage.googleapis.com/v0/b/healthtree-production.appspot.com/o/gallery%2Fpublic%2F1682188565594_217313db-c2d5-4ac9-8426-78e017798142_dca2a66a-69e0-470f-9d72-a578050fee9e.jpg?alt=media)
Megan introduces the agenda of the event and featured speaker Dr. Kerry Rogers.
![The panelist Kerry Rogers, MD](https://firebasestorage.googleapis.com/v0/b/healthtree-production.appspot.com/o/gallery%2Fpublic%2F7147_beb996c3-da49-4af6-bda8-eda8d38d7084.jpg?alt=media)
Dr. Rogers shares insight about treatment options available to relapsed and refractory CLL patients.
![The panelist Kerry Rogers, MD](https://firebasestorage.googleapis.com/v0/b/healthtree-production.appspot.com/o/gallery%2Fpublic%2F7147_beb996c3-da49-4af6-bda8-eda8d38d7084.jpg?alt=media)
Dr. Rogers shares insight about treatment options available to relapsed and refractory CLL patients.
![The panelist Audience](https://firebasestorage.googleapis.com/v0/b/healthtree-production.appspot.com/o/gallery%2Fpublic%2FCommunity%20Logo_cb6cf053-9ce8-4691-ad8c-c0b54d625712.png?alt=media)
Type your questions in the chat, and Dr. Rogers will answer them!
![The panelist Audience](https://firebasestorage.googleapis.com/v0/b/healthtree-production.appspot.com/o/gallery%2Fpublic%2FCommunity%20Logo_cb6cf053-9ce8-4691-ad8c-c0b54d625712.png?alt=media)
Type your questions in the chat, and Dr. Rogers will answer them!
Speakers & Moderators
![The panelist Kerry Rogers, MD](https://firebasestorage.googleapis.com/v0/b/healthtree-production.appspot.com/o/gallery%2Fpublic%2F7147_beb996c3-da49-4af6-bda8-eda8d38d7084.jpg?alt=media)
Dr. Kerry Rogers is a hematologist-oncologist dedicated to advancing the care and treatment of patients with chronic lymphocytic leukemia (CLL) and autoimmune cytopenias. Following her initial medical education at Chicago Medical School, she completed her residency in internal medicine at the University of Michigan. She then undertook fellowship at The Ohio State University in hematology and oncology, and after completion of her training, she was delighted to join the staff at the OSUCCC – James. In addition to clinical work, she spends time teaching medical students and resident physicians as an assistant professor in the Department of Hematology. As a member of the Leukemia Research Program at the OSUCCC – James, she conducts research in the Experimental Hematology Laboratory developing novel therapeutics for autoimmune cytopenias. Her research group has an interest in finding optimal strategies for the use of BTK inhibitors, including studying resistance, combination therapies and treatment discontinuation. She is currently the principal investigator on four open and two pending clinical trials in this area, including two investigator-sponsored trials and an NCI study. She has also written several articles for publication in medical journals such as Leukemia and Cancer Cell, and has prepared numerous abstracts and posters for presentations. What she loves most about The James is working with very passionate and committed team members to give patients the very best care. She feels that communication is a key aspect to providing the best medical care and enjoys spending time with her patients most of all.
![The panelist Megan Heaps](https://firebasestorage.googleapis.com/v0/b/healthtree-production.appspot.com/o/gallery%2Fpublic%2F1682188565594_217313db-c2d5-4ac9-8426-78e017798142_dca2a66a-69e0-470f-9d72-a578050fee9e.jpg?alt=media)
Megan joined HealthTree as the Program Manager for CLL in 2022. She is the daughter of a blood cancer patient and has found a passion for helping support patients and caregivers to advance research for their cure and improve their quality of life.
Have Any Questions?
Thank you for your interest in the event. If you have any questions, we would love to help!
Feel free to give us a call or send us a message below.
Get In Touch With Us
1-800-709-1113
Support@healthtree.org
![newsletter icon](https://static.healthtree.org/icons/newsletter-icon.png)
Get the latest thought leadership on your Chronic Lymphocytic Leukemia delivered straight to your inbox
Subscribe to the weekly newsletter for news, stories, clinical trial updates, and helpful resources and events with cancer experts.
Thanks to our HealthTree Community for Chronic Lymphocytic Leukemia Sponsors:
![Abbvie](https://firebasestorage.googleapis.com/v0/b/healthtree-production.appspot.com/o/gallery%2Fpublic%2Fabbvie%20bigger_c5e4f4af-fb3c-45ca-b9f0-831fb4c5f968.jpeg?alt=media)
![Genentech](https://firebasestorage.googleapis.com/v0/b/healthtree-production.appspot.com/o/gallery%2Fpublic%2Fgenentech_b71578d3-7dbe-46d2-9823-4eabf80f387b.png?alt=media)